scispace - formally typeset
F

Francisco Martinez-Murillo

Researcher at Johns Hopkins University

Publications -  17
Citations -  5531

Francisco Martinez-Murillo is an academic researcher from Johns Hopkins University. The author has contributed to research in topics: Gene expression profiling & Gene. The author has an hindex of 14, co-authored 17 publications receiving 5340 citations. Previous affiliations of Francisco Martinez-Murillo include Food and Drug Administration & Johns Hopkins University School of Medicine.

Papers
More filters
Journal ArticleDOI

A Model-Based Background Adjustment for Oligonucleotide Expression Arrays

TL;DR: The default ad hoc adjustment, provided as part of the Affymetrix system, can be improved through the use of estimators derived from a statistical model that uses probe sequence information, which greatly improves the performance of the technology in various practical applications.
Journal ArticleDOI

Multiple-laboratory comparison of microarray platforms

TL;DR: A consortium of ten laboratories from the Washington, DC–Baltimore, USA, area was formed to compare data obtained from three widely used platforms using identical RNA samples to demonstrate that there are relatively large differences in data obtained in labs using the same platform, but that the results from the best-performing labs agree rather well.
Journal ArticleDOI

Nonsense surveillance regulates expression of diverse classes of mammalian transcripts and mutes genomic noise.

TL;DR: Novel results document that nonsense surveillance is a crucial post-transcriptional regulatory event that influences the expression of broad classes of physiologic transcripts, has been functionally incorporated into essential homeostatic mechanisms and suppresses expression of evolutionary remnants.
Journal ArticleDOI

The Microarray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models

Leming Shi, +201 more
- 01 Aug 2010 - 
TL;DR: P predictive models for classifying a sample with respect to one of 13 endpoints indicative of lung or liver toxicity in rodents, or of breast cancer, multiple myeloma or neuroblastoma in humans are generated.